OncoMatch/Clinical Trials/NCT06689163
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Is NCT06689163 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including HRS-1167 tablets and Abiraterone Acetate tablets（II） for prostate cancer.
Treatment: HRS-1167 tablets · Abiraterone Acetate tablets（II） · Prednisone Acetate tablets — The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor therapy
Exception: anti-tumor proprietary Chinese medicine allowed if interval ≥ 2 weeks
Received systemic antitumor therapy 4 weeks before starting study treatment; ... Patients who had previously received anti-tumor proprietary Chinese medicine could be enrolled if the interval between the end of treatment and the first study was not less than 2 weeks.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify